Compounds for improved viral transduction
Assigneebluebird bio, Inc.
InventorsGarrett Collins Heffner, Abraham Isaac Bassan
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for improving the efficacy of viral transduction of cells. More particularly, the present invention provides methods and materials useful for safely and reliably improving the efficiency of methods for transducing cells, such as human hematopoietic stem cells (HSC), with viruses and/or viral vectors. The compositions and methods are useful for therapeutic indications amenable to treatment with hematopoietic stem cell gene therapies.
Claims29
A method for increasing the lentiviral transduction efficiency of CD34+ hematopoietic stem and/or progenitor cells comprising:
- contacting the CD34+ hematopoietic stem and/or progenitor cells with a culture medium comprising a lentivirus and prostaglandin E2 (PGE2), 16,16-dimethyl PGE2, or an analogue thereof in vitro,
- wherein the lentiviral transduction efficiency is increased in the CD34+ hematopoietic stem and/or progenitor cells contacted with the culture medium compared to the lentiviral transduction efficiency of CD34+ hematopoietic stem and/or progenitor cells contacted with a culture medium comprising the lentivirus in the absence of PGE2, 16,16-dimethyl PGE2, or an analogue thereof.
A method for increasing the lentiviral transduction efficiency of CD34+ hematopoietic stem and/or progenitor cells comprising:
- contacting the CD34+ hematopoietic stem and/or progenitor cells with a culture medium comprising a lentivirus and PGE2 in vitro,
- wherein the lentiviral transduction efficiency is increased in the CD34+ hematopoietic stem and/or progenitor cells contacted with the culture medium compared to the lentiviral transduction efficiency of CD34+ hematopoietic stem and/or progenitor cells contacted with a culture medium comprising the lentivirus in the absence of PGE2.
A method for increasing the lentiviral transduction efficiency of CD34+ hematopoietic stem and/or progenitor cells comprising:
- contacting the CD34+ hematopoietic stem and/or progenitor cells with a culture medium comprising a lentivirus and 16,16-dimethyl PGE2 in vitro,
- wherein the lentiviral transduction efficiency is increased in the CD34+ hematopoietic stem and/or progenitor cells contacted with the culture medium compared to the lentiviral transduction efficiency of CD34+ hematopoietic stem and/or progenitor cells contacted with a culture medium comprising the lentivirus in the absence of 16,16-dimethyl PGE2.
Dependencies are inferred from the claim text.